SEC Form 4 · accession 0001213900-16-012630
Actinium Pharmaceuticals, Inc. · ATNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sergio Traversa
Director
Period of report
Apr 16, 2016
Accepted (ET)
Apr 18, 2016 · 5:24 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001388320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 14, 2016 | P | 2,000 | $2.02 | A | 2,000 | D | |
| Common Stock | Apr 15, 2016 | P | 1,000 | $2.02 | A | 3,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to purchase common stockF1 | $1.99 | Apr 15, 2016 | A | 75,000 | A | — | Apr 15, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant.